Laboratorios Rubió is a company that is currently
undergoing a process of expansion and growth
Revenue (in thousands of €)
Laboratorios Rubió is a company in the process of expansion and growth. Ascending progression of turnover is an indicator of the good work done. Our strategic plan focuses on internationalization and R&D for the development of new products.
The turnover of 2020 totaled € 55.2 million, representing an annual increase of 16%. By markets, in Spain the increase has been 14% and 22% internationally.
2021 is expected to continue the growth in turnover reaching 60 M€, 9%.
The company’s staff is made up of 150 people—11,3% more than in 2015—with the greatest amount of growth happening in the sales and industrial operations departments.
Laboratorios Rubió is a company that places its trust in the people who make up its organisation, recognises their professional value and dedicates resources to ensure that a good working environment is maintained by fostering opportunities, personal development and a good work-life balance.
concentrates its investments in expanding production capacity and R & D. In 2021, the expansion of the production facilities has begun, which in three years will allow us to practically double our capacity. We also continue to invest in various R&D projects for both the European and American markets.
Investments (in thousands of €)
Created in 2014, this subsidiary acts as a “patent box” in order to boost the Laboratorios Rubió’s R&D&i department. Within this sphere of activity, the company’s number one strategy is based on expanding the lifecycle of their own products, collaborating in new research programmes whose goals tie in with the company’s own therapeutic goals, and establishing strategic alliances with research foundations in related fields.
Biosfer Teslab, a spin-off of the Universidad Rovira i Virgili (URV) and the Institut d’Investigació Sanitària Pere Virgili (IISPV), is one of Laboratorios Rubió’s investee companies, which specialises in developing in vitro diagnostic tests to improve cardiovascular assessment in high-risk patients.